Umbilical cord blood (UCB) is an alternative source of hematopoietic stem cells in allogeneic transplantation for patients lacking HLA-matched donors. Widespread banking of UCB is increasing worldwide and has generated new issues in the assessment of graft adequacy. The presence of maternal cells in UCB has been previously documented although the ability to confer diseaserelated phenotypes in the infant is unknown.
1 Transplantation of UCB containing maternal T-lymphocytes or malignant leukemic cells could increase the risk of graft-versus-host disease (GVHD) or leukemia in the recipient. We report a case of AML occurring in a pregnant female and our efforts to identify contaminating leukemic cells in the UCB are described. Our case illustrates an uncommon but important issue in the quality assurance of stem cell grafts.
A 21-year-old female patient developed AML (FAB subtype M0) at 35 weeks gestation. She developed peripheral pancytopenia associated with a bone marrow aspirate containing greater than 30% CD33( þ )CD19( þ ) leukemic blasts. Cytogenetic studies revealed a normal female karyotype. Cytotoxic chemotherapy was withheld until spontaneous vaginal delivery occurred 2 weeks later. Initial bloodwork of the newborn boy revealed a normal complete blood count and differential. Immunophenotype analysis of the peripheral blood and UCB specimens was also normal with no detectable Quality assurance issues will be increasingly important as UCB banking increases. The possibility of maternal cells harming or contaminating UCB grafts may be an important consideration. Previous groups have demonstrated that contaminating maternal T cells are found in 1/47-10/49 patients and that the levels could potentially contribute to GVHD in susceptible recipients.
2,3 Risks related to transmitting disease from the mother to a transplant recipient remain uncertain. Culturing UCB is under investigation as a means to expand the number of early repopulating cells and whether maternal cells will be expanded preferentially remains unclear. One group, however, reported that levels of maternal cells in UCB actually decreased during 14 days of ex vivo culture. 4 Human leukemia-initiating cells can be transplanted into irradiated NOD/SCID mice and reproduce a similar leukemic phenotype for most AML subtypes.
5 FAB subtype M0, high-risk cytogenetic abnormalities, refractoriness to therapy, high initial peripheral leukocyte counts and therapy-induced AML are all associated with increased likelihood of establishing the leukemic phenotype after transplantation into NOD/SCID mice.
6 Levels of engraftment appear to relate to proliferative capacity of the leukemic stem cell rather than a measure of the leukemic burden. 6 The estimated frequency of detecting leukemic stem cells in the NOD/SCID transplant model was between 0.2 and 200 per 10 6 unfractionated peripheral blood mononuclear cells based on data from a limiting dilution analysis.
5 Taken together, the absence of NOD/SCID leukemia-initiating cells, the lack of AML blasts on UCB immunophenotyping and undetectable maternal cells in the UCB by cytogenetic analysis all strongly suggest that leukemic cells were not contaminating the UCB in this case. 
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